Eli Lilly & Co. (LLY): If You’re Going to Fail, Fail Quickly

Lilly calls active as shares soar; Put spreads constructed on Verizon, AT&TIn goes another drug into the Eli Lilly & Co. (NYSE:LLY) trash can. The pharma is dropping development of tabalumab for rheumatoid arthritis.

It’s not particularly surprising given that the drug failed a phase 3 trial in December, but it’s still disappointing for a company that could really use a positive result. Tabalumab joins in the trash can Alimta for lung cancer, pomaglumetad methionil for schizophrenia, and Forteo for back pain, which all recently failed clinical trials.

The trial results released in December showed that tabalumab failed to help patients who didn’t respond to methotrexate, a drug typically used early in disease progression. Based on that result, Eli Lilly decided to take an early look at its other study in patients who failed to respond to one or more tumor necrosis factor inhibitors — AbbVie Inc (NYSE:ABBV)‘s Humira, Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK)‘s Remicade, or Pfizer Inc. (NYSE:PFE) and Amgen, Inc. (NASDAQ:AMGN)‘s Enbrel — that are typically used later in the progression of rheumatoid arthritis. The interim peek at the data showed that it was futile to continue, so Lilly has decided to drop development of tabalumab in rheumatoid arthritis.

While Humira, Remicade, and Enbrel are safe from future competition from tabalumab, GlaxoSmithKline plc (ADR) (NYSE:GSK) still needs to watch its back. Eli Lilly is continuing development of tabalumab as a treatment for lupus. The drug attacks the same target — B cell activating factor, or BAFF — as Glaxo’s Benlysta, so the chance of success is higher for lupus.

Glaxo and its acquired partner Human Genome Sciences tested Benlysta on rheumatoid arthritis where it was shown to be ineffective, so it shouldn’t come as much of a surprise that tabalumab was ineffective as well.

I’m not sure exactly what led Lilly to believe it could succeed where Benlysta had failed, perhaps it felt tabalumab was a better inhibitor and could therefore succeed. Hindsight is 20/20, but it seems likely that BAFF isn’t a good target for rheumatoid arthritis. The only good decision we can say Lilly made in the development of tabalumab for rheumatoid arthritis is that it ended development early, saving money by not letting the trials go to completion before realizing that it was a dead end.

The article If You’re Going to Fail, Fail Quickly originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!